trending Market Intelligence /marketintelligence/en/news-insights/trending/p_z38ewqtjzwh6fxkn86ag2 content esgSubNav
In This List

Biohaven Pharmaceutical Holding prices $125M common stock offering

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Biohaven Pharmaceutical Holding prices $125M common stock offering

Biohaven Pharmaceutical Holding Co. Ltd. priced an underwritten public offering of 3,355,705 common shares at $37.25 apiece.

Gross proceeds from the offering are expected to be $125 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the company.

Underwriters have a 30-day option to purchase up to an additional 503,355 common shares at the public offering price, less underwriting discounts and commissions.

The offering is expected to close on Dec. 17, subject to customary closing conditions.

Goldman Sachs & Co. LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, with Morgan Stanley and Cantor Fitzgerald & Co. as book runners and William Blair as co-manager.

New Haven, Conn.-based Biohaven Pharmaceutical Holding is a clinical‑stage biopharmaceutical company which develops product candidates targeting migraine and neurological diseases, including rare disorders.